Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KBTEO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
iMGN529
|
|||||
| Synonyms |
IMGN529
Click to Show/Hide
|
|||||
| Organization |
DAIICHI SAMKO COMPANY, LIMITED
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Naratuximab
|
Antibody Info | ||||
| Antigen Name |
Leukocyte antigen CD37 (CD37)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 20% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 10, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates IMGN529 was intravenously administered at a dose of 3 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.
Click to Show/Hide
|
||||
| In Vivo Model | OCI-LY7 (DSMZ) female SCID mouse model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 20% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 8, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates IMGN529 was intravenously administered at a dose of 3 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.
Click to Show/Hide
|
||||
| In Vivo Model | WSU-DLCL2 (DSMZ) female SCID mouse model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 20% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37-positive human diffuse large B-cell lymphoma cell line NU-DUL-1 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 14, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates IMGN529 was intravenously administered at a dose of 3 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.
Click to Show/Hide
|
||||
| In Vivo Model | NU-DUL-1 (DSMZ) female SCID mouse model | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 20% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37- positive human follicular lymphoma cell line DOHH-2 (DSMZ) was subcutaneously inoculated at a dose of 1x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 21, the mice were randomly grouped. On the day of grouping, IMGN529 was intravenously administered to the tail of each mouse at 3 mg/kg.
|
||||
| In Vivo Model | DOHH-2 (DSMZ) female SCID mouse model | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 30% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 16, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates IMGN529 was intravenously administered at a dose of 10 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.
Click to Show/Hide
|
||||
| In Vivo Model | SU-DHL-8 (ATCC) female SCID mouse model | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | < 30% | Positive CD37 expression (CD37+++/++) | ||
| Method Description |
CD37- positive human chronic lymphocytic leukemia cell line JVM-3 (DSMZ) was subcutaneously inoculated at a dose of 3x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 13, the mice were randomly grouped. On the day of grouping, each antibody-drug conjugate was intravenously administered to the tail of each mouse.
|
||||
| In Vivo Model | JVM-3 (DSMZ) female SCID mouse model | ||||